A sensitive and inexpensive high-resolution melting-based testing algorithm for diagnosis of transient abnormal myelopoiesis and myeloid leukemia of Down syndrome

Pediatr Blood Cancer. 2022 Nov;69(11):e29866. doi: 10.1002/pbc.29866. Epub 2022 Jul 11.

Abstract

Patients with Down syndrome (DS) are commonly affected by a pre-leukemic disorder known as transient abnormal myelopoiesis (TAM). This condition usually undergoes spontaneous remission within the first 2 months after birth; however, in children under 5, 20%-30% of cases evolve to myeloid leukemia of Down syndrome (ML-DS). TAM and ML-DS are caused by co-operation between trisomy 21 and acquired mutations in the GATA1 gene. Currently, only next-generation sequencing (NGS)-based methodologies are sufficiently sensitive for diagnosis in samples with small GATA1 mutant clones (≤10% blasts). Alternatively, this study presents research on a new, fast, sensitive, and inexpensive high-resolution melting (HRM)-based diagnostic approach that allows the detection of most cases of GATA1 mutations, including silent TAM. The algorithm first uses flow cytometry for blast count, followed by HRM and Sanger sequencing to search for mutations on exons 2 and 3 of GATA1. We analyzed 138 samples of DS patients: 110 of asymptomatic neonates, 10 suspected of having TAM, and 18 suspected of having ML-DS. Our algorithm enabled the identification of 33 mutant samples, among them five cases of silent TAM (5/110) and seven cases of ML-DS (7/18) with blast count ≤10%, in which GATA1 alterations were easily detected by HRM. Depending on the type of genetic variation and its location, our methodology reached sensitivity similar to that obtained by NGS (0.3%) at a considerably reduced time and cost, thus making it accessible worldwide.

Keywords: Down syndrome; GATA1; HRM; ML-DS; TAM; diagnostic algorithm.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Algorithms
  • Child
  • Down Syndrome* / complications
  • Down Syndrome* / diagnosis
  • Down Syndrome* / genetics
  • GATA1 Transcription Factor / genetics
  • Humans
  • Infant, Newborn
  • Leukemia, Myeloid* / genetics
  • Leukemoid Reaction* / diagnosis
  • Leukemoid Reaction* / genetics
  • Mutation

Substances

  • GATA1 Transcription Factor

Supplementary concepts

  • Myeloproliferative Syndrome, Transient